Literature DB >> 19092759

Respiratory syncytial virus activity-- United States, July 2007-December 2008.

.   

Abstract

Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in children aged <1 year and is a major cause of respiratory illness in older adults. RSV is transmitted person-to-person via close contact, droplets, and fomites. Each year in the United States, an estimated 75,000-125,000 children aged <1 year are hospitalized with RSV. Those at increased risk for hospitalization include premature infants meeting certain criteria and persons of any age with compromised respiratory, cardiac, and immune systems. RSV incidence follows a seasonal pattern. In temperate climates, the RSV season generally occurs during the fall, winter, and spring months. However, the timing of RSV circulation can vary by location and year. CDC analyzed laboratory data from the National Respiratory and Enteric Virus Surveillance System (NREVSS) to summarize RSV temporal and geographic trends in the United States during the weeks ending July 7, 2007--June 28, 2008, and for the first 5 months of the current reporting season (the weeks ending July 5-December 6, 2008). This report describes the results of that analysis, which indicated that the 2007-08 RSV season onset for the 10 U.S. Department of Health and Human Services (HHS) regions and Florida ranged from early July to mid-December, and the season offset ranged from late January to mid-April; the current 2008-09 season onset occurred in eight of the 10 HHS regions by December 6, 2008. These findings support previous observations that the RSV season not only varies by location, but can vary by year.

Entities:  

Mesh:

Year:  2008        PMID: 19092759

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  13 in total

Review 1.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  Effect of young sibling visitation on respiratory syncytial virus activity in a NICU.

Authors:  A M Peluso; B A Harnish; N S Miller; E R Cooper; A M Fujii
Journal:  J Perinatol       Date:  2015-04-02       Impact factor: 2.521

3.  Predicting the start week of respiratory syncytial virus outbreaks using real time weather variables.

Authors:  Nephi A Walton; Mollie R Poynton; Per H Gesteland; Chris Maloney; Catherine Staes; Julio C Facelli
Journal:  BMC Med Inform Decis Mak       Date:  2010-11-02       Impact factor: 2.796

4.  Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.

Authors:  Hong Zhou; William W Thompson; Cecile G Viboud; Corinne M Ringholz; Po-Yung Cheng; Claudia Steiner; Glen R Abedi; Larry J Anderson; Lynnette Brammer; David K Shay
Journal:  Clin Infect Dis       Date:  2012-04-10       Impact factor: 9.079

Review 5.  Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

6.  Validation of statistical models for estimating hospitalization associated with influenza and other respiratory viruses.

Authors:  Lin Yang; Susan S Chiu; King-Pan Chan; Kwok-Hung Chan; Wilfred Hing-Sang Wong; J S Malik Peiris; Chit-Ming Wong
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

Review 7.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.558

8.  Respiratory syncytial virus surveillance in the United States, 2007-2012: results from a national surveillance system.

Authors:  Catherine Balderston McGuiness; Marnie L Boron; Brett Saunders; Laurel Edelman; Veena R Kumar; Karma M Rabon-Stith
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

9.  Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar.

Authors:  Ahmad Abushahin; Ibrahim Janahi; Amjad Tuffaha
Journal:  Int J Gen Med       Date:  2018-01-31

10.  Mortality in children hospitalised with respiratory syncytial virus infection in Singapore.

Authors:  Ming Wei Lee; Anne En Goh
Journal:  Singapore Med J       Date:  2020-05-27       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.